Metabolic News Weekly: July 2, 2024
Boehringer Ingelheim launches phase 1 trial for triple-action obesity drug July 1, 2024 / Boehringer Ingelheim / Obesity / Triple-action Obesity Drug / Clinical Trials / Obesity Epidemic Boehringer Ingelheim, with Gubra, launches a Phase 1 trial for BI 3034701,...